BioSpectra announced that it has expanded its capacity for the synthesis and purification of active pharmaceutical ingredients (APIs) and excipients with low bioburden and low endotoxin (LBLE) requirements in an April 4, 2018 press release. These products, intended for use in parenteral dr
